Akari Therapeutics Plc Quarterly Operating Income (Loss) in USD from Q1 2014 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Akari Therapeutics Plc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2014 to Q4 2024.
  • Akari Therapeutics Plc Operating Income (Loss) for the quarter ending December 31, 2024 was -$11.3M, a 61.1% decline year-over-year.
  • Akari Therapeutics Plc Operating Income (Loss) for the twelve months ending December 31, 2024 was -$21.6M, a 28.8% decline year-over-year.
  • Akari Therapeutics Plc annual Operating Income (Loss) for 2024 was -$21.6M, a 28.8% decline from 2023.
  • Akari Therapeutics Plc annual Operating Income (Loss) for 2023 was -$16.8M, a 41.8% decline from 2022.
  • Akari Therapeutics Plc annual Operating Income (Loss) for 2022 was -$11.8M, a 31.2% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$21.6M -$11.3M -$4.3M -61.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-04-15
Q3 2024 -$17.3M -$2.93M -$420K -16.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-19
Q2 2024 -$16.9M -$1.39M +$1.28M +47.9% Apr 1, 2024 Jun 30, 2024 8-K 2024-09-06
Q1 2024 -$18.2M -$5.99M -$1.4M -30.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$16.8M -$7.03M Oct 1, 2023 Dec 31, 2023 10-K 2025-04-15
Q3 2023 -$2.51M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-19
Q2 2023 -$2.67M +$3.15M +54.1% Apr 1, 2023 Jun 30, 2023 8-K 2024-09-06
Q1 2023 -$4.59M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q2 2022 -$5.82M -$1.49M -34.3% Apr 1, 2022 Jun 30, 2022 6-K 2022-09-27
Q2 2021 -$4.33M +$1.58M +26.8% Apr 1, 2021 Jun 30, 2021 6-K 2022-09-27
Q4 2020 -$18M -$6.9M +$931K +11.9% Oct 1, 2020 Dec 31, 2020 20-F 2023-05-01
Q3 2020 -$18.9M -$247K +$2.87M +92.1% Jul 1, 2020 Sep 30, 2020 20-F 2021-04-21
Q2 2020 -$21.8M -$5.91M +$120K +1.99% Apr 1, 2020 Jun 30, 2020 6-K 2021-09-22
Q1 2020 -$21.9M -$4.93M -$4.94M -41289% Jan 1, 2020 Mar 31, 2020 20-F 2021-04-21
Q4 2019 -$17M -$7.83M Oct 1, 2019 Dec 31, 2019 20-F 2022-05-16
Q3 2019 -$3.12M Jul 1, 2019 Sep 30, 2019 20-F 2021-04-21
Q2 2019 -$6.03M +$1.95M +24.4% Apr 1, 2019 Jun 30, 2019 20-F 2021-04-21
Q1 2019 $12K Jan 1, 2019 Mar 31, 2019 20-F 2021-04-21
Q2 2018 -$7.98M -$630K -8.57% Apr 1, 2018 Jun 30, 2018 6-K 2019-08-29
Q2 2017 -$7.35M +$171K +2.27% Apr 1, 2017 Jun 30, 2017 6-K 2018-09-27
Q2 2016 -$39M -$7.52M -$6.21M -473% Apr 1, 2016 Jun 30, 2016 6-K 2017-08-10
Q1 2016 -$32.8M -$3.85M -$2.2M -133% Jan 1, 2016 Mar 31, 2016 10-Q 2016-05-12
Q4 2015 -$30.6M -$4.29M -$6.8M -271% Oct 1, 2015 Dec 31, 2015 20-F 2018-07-18
Q3 2015 -$23.8M -$23.3M -$23.1M -10599% Jul 1, 2015 Sep 30, 2015 10-Q 2015-11-23
Q2 2015 -$673K -$1.31M +$1.02M +43.7% Apr 1, 2015 Jun 30, 2015 6-K 2017-04-14
Q1 2015 -$1.69M -$1.65M +$228K +12.1% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-12
Q4 2014 -$1.92M $2.51M Oct 1, 2014 Dec 31, 2014 20-F 2017-03-31
Q3 2014 -$218K Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-23
Q2 2014 -$2.33M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-12
Q1 2014 -$1.88M Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.